Literature DB >> 16132527

Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas: participation of nuclear factor-kappaB in upregulation of syndecan-1 expression.

Arata Watanabe1, Tadashi Mabuchi, Eiji Satoh, Koro Furuya, Lei Zhang, Shuichiro Maeda, Hirofumi Naganuma.   

Abstract

Invasion of tumor cells into the surrounding normal brain tissues is a prominent feature of malignant gliomas. Malignant glioma cells secrete thrombospondin-1 which participates in the motility of glioma cells and binds cell surface heparan sulfate proteoglycan. To clarify the invasion mechanism of tumor cells, expression of the syndecans (syndecan-1, -2, -3, and -4), a major cell surface heparan sulfate proteoglycan family, was analyzed in malignant gliomas. Involvement of nuclear factor-kappaB (NF-kappaB) on syndecan-1 expression was also investigated. Using reverse transcription-PCR, the authors analyzed the expression of syndecan-1, -2, -3, and -4 in 10 malignant glioma cell lines, 2 glioblastoma specimens, and 2 normal brain specimens. All malignant glioma cell lines and glioblastoma specimens expressed all types of syndecan mRNA, except in one glioma cell line that lacked syndecan-3 expression. On the other hand, normal brain specimens expressed syndecan-2, -3, and -4 mRNA, but did not syndecan-1 mRNA. Syndecan-1 protein was localized in the cell surface of all malignant glioma cell lines by flow cytometry. Various levels of active nuclear factor-kappa B (NF-kappaB) was detected in all malignant glioma cell lines using immunoblotting. The expression of active NF-kappaB and syndecan-1 increased in U251 glioma cells after tumor necrosis factor-alpha or interleukin-1beta treatment, which can activate NF-kappaB. The amplification of active NF-kappaB and syndecan-1 by tumor necrosis factor-alpha or interleukin-1beta was suppressed by an inhibitor of NF-kappaB activation (emodin). Emodin also downregulated the expression of syndecan-1 mRNA in U251 cells. These results indicate that malignant glioma cells express all types of syndecans and suggest that NF-kappaB participates in the upregulation of the syndecan-1 expression at the transcriptional level, and increased expression of syndecan-1 could associate with extracellular matrices including thrombospondin-1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16132527     DOI: 10.1007/s11060-005-9010-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  27 in total

Review 1.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

Review 2.  Syndecans: synergistic activators of cell adhesion.

Authors:  A Woods; J R Couchman
Journal:  Trends Cell Biol       Date:  1998-05       Impact factor: 20.808

3.  Expression of syndecan-1 is common in human lung cancers independent of expression of epidermal growth factor receptor.

Authors:  E Toyoshima; Y Ohsaki; Y Nishigaki; Y Fujimoto; Y Kohgo; K Kikuchi
Journal:  Lung Cancer       Date:  2001 Feb-Mar       Impact factor: 5.705

4.  Aberrant nuclear factor-kappaB activity and its participation in the growth of human malignant astrocytoma.

Authors:  Shoichi Nagai; Kazuo Washiyama; Masanori Kurimoto; Akira Takaku; Shunro Endo; Toshiro Kumanishi
Journal:  J Neurosurg       Date:  2002-05       Impact factor: 5.115

5.  Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns.

Authors:  C W Kim; O A Goldberger; R L Gallo; M Bernfield
Journal:  Mol Biol Cell       Date:  1994-07       Impact factor: 4.138

6.  Participation of thrombospondin-1 in the activation of latent transforming growth factor-beta in malignant glioma cells.

Authors:  A Sasaki; H Naganuma; E Satoh; T Kawataki; K Amagasaki; H Nukui
Journal:  Neurol Med Chir (Tokyo)       Date:  2001-05       Impact factor: 1.742

Review 7.  Regulation of tumor growth and metastasis by thrombospondin-1.

Authors:  D D Roberts
Journal:  FASEB J       Date:  1996-08       Impact factor: 5.191

8.  Establishment and partial characterization of five malignant glioma cell lines.

Authors:  Lei Zhang; Tetsu Yamane; Eiji Satoh; Kenichi Amagasaki; Tomoyuki Kawataki; Takayuki Asahara; Koro Furuya; Hideaki Nukui; Hirofumi Naganuma
Journal:  Neuropathology       Date:  2005-06       Impact factor: 1.906

9.  A role for syndecan-1 in coupling fascin spike formation by thrombospondin-1.

Authors:  J C Adams; N Kureishy; A L Taylor
Journal:  J Cell Biol       Date:  2001-03-19       Impact factor: 10.539

10.  Syndecan-1 mediates cell spreading in transfected human lymphoblastoid (Raji) cells.

Authors:  C S Lebakken; A C Rapraeger
Journal:  J Cell Biol       Date:  1996-03       Impact factor: 10.539

View more
  28 in total

1.  Syndecan-1-dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer.

Authors:  Yunping Hu; Haiguo Sun; Rick T Owens; Zhennan Gu; Jansheng Wu; Yong Q Chen; Joseph T O'Flaherty; Iris J Edwards
Journal:  Neoplasia       Date:  2010-10       Impact factor: 5.715

Review 2.  Glycosylation alterations in lung and brain cancer.

Authors:  Hassan Lemjabbar-Alaoui; Andrew McKinney; Yi-Wei Yang; Vy M Tran; Joanna J Phillips
Journal:  Adv Cancer Res       Date:  2015-02-07       Impact factor: 6.242

3.  Chemical Tumor Biology of Heparan Sulfate Proteoglycans.

Authors:  Karthik Raman; Balagurunathan Kuberan
Journal:  Curr Chem Biol       Date:  2010-01-01

Review 4.  Proteoglycans in prostate cancer.

Authors:  Iris J Edwards
Journal:  Nat Rev Urol       Date:  2012-02-21       Impact factor: 14.432

5.  Heparan sulfate sulfatase SULF2 regulates PDGFRα signaling and growth in human and mouse malignant glioma.

Authors:  Joanna J Phillips; Emmanuelle Huillard; Aaron E Robinson; Anna Ward; David H Lum; Mei-Yin Polley; Steven D Rosen; David H Rowitch; Zena Werb
Journal:  J Clin Invest       Date:  2012-02-01       Impact factor: 14.808

6.  Heparan sulfate accumulation and perlecan/HSPG2 up-regulation in tumour tissue predict low relapse-free survival for patients with glioblastoma.

Authors:  Galina M Kazanskaya; Alexandra Y Tsidulko; Alexander M Volkov; Roman S Kiselev; Anastasia V Suhovskih; Vyacheslav V Kobozev; Alexei S Gaytan; Svetlana V Aidagulova; Alexei L Krivoshapkin; Elvira V Grigorieva
Journal:  Histochem Cell Biol       Date:  2018-01-10       Impact factor: 4.304

7.  Syndecan-1 expression in human glioma is correlated with advanced tumor progression and poor prognosis.

Authors:  Yimin Xu; Jun Yuan; Ziheng Zhang; Lvbiao Lin; Shengliang Xu
Journal:  Mol Biol Rep       Date:  2012-06-20       Impact factor: 2.316

Review 8.  Proteoglycans and their roles in brain cancer.

Authors:  Anna Wade; Aaron E Robinson; Jane R Engler; Claudia Petritsch; C David James; Joanna J Phillips
Journal:  FEBS J       Date:  2013-02-06       Impact factor: 5.542

Review 9.  Role of hyaluronan in glioma invasion.

Authors:  Jong Bae Park; Hee-Jin Kwak; Seung-Hoon Lee
Journal:  Cell Adh Migr       Date:  2008-07-21       Impact factor: 3.405

10.  MDA-9/syntenin is a key regulator of glioma pathogenesis.

Authors:  Timothy P Kegelman; Swadesh K Das; Bin Hu; Manny D Bacolod; Christine E Fuller; Mitchell E Menezes; Luni Emdad; Santanu Dasgupta; Albert S Baldwin; Jeffrey N Bruce; Paul Dent; Maurizio Pellecchia; Devanand Sarkar; Paul B Fisher
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.